Key result
Surgical SAPIEN-3 Ultra implantation for severe MAC shows 0% operative mortality and no strokes.
Why the study?
Mitral valve surgery in extensive mitral annular calcification remains challenging, and hybrid open surgical transcatheter valve implantation is off-label and needs standardization.
Does surgical implantation of a transcatheter aortic valve in the mitral position (SViMAC) improve outcomes in high-risk patients with severe mitral annular calcification?
Cohort (n=7)
No
Does surgical implantation of a transcatheter aortic valve in the mitral position (SViMAC) improve outcomes in high-risk patients with severe mitral annular calcification?
Surgical implantation of a transcatheter balloon-expandable valve in the mitral position is a feasible technique for high-risk patients with severe mitral annular calcification, with excellent intraoperative survival but high mid-term mortality reflecting underlying comorbidities.
Hybrid SViMAC feasible with zero intraoperative mortality in small high-risk MAC cohort; hypothesis-generating for larger trials.
Mitral valve surgery in patients with extensive mitral annular calcification remains challenging. Different surgical approaches have been described: from a complete decalcification and reconstruction of the mitral annulus to other techniques where a full debridement was avoided to minimize the risk of possible peri-operative complications. In the current era of transcatheter valve implantation, the issue of mitral annulus calcification has been addressed by some with the adoption of a hybrid technique, where a transcatheter aortic valve is implanted in mitral position, during open heart surgery. This technique is emerging as a treatment option for high-risk patients although it is still an off-label procedure and needs further standardization. We describe here our surgical technique to implant a SAPIEN-3 Ultra™ in mitral position, addressing some of the key points in the surgical technique: the appropriate sizing and the phase of deployment of the prosthesis.
No takes yet. Share an insight, caveat, or question.
Lucchese et al. (2026) conducted a cohort in Severe mitral annular calcification (MAC) (n=7). Surgical valve in MAC (SViMAC) using SAPIEN-3 Ultra was evaluated on All-cause operative mortality (in-hospital or 30-day mortality). Surgical implantation of a SAPIEN-3 Ultra transcatheter valve in 7 high-risk patients with severe mitral annular calcification resulted in 0% intraoperative mortality and no stroke events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: